OFK.F Orion Oyj

Healthcare Pharmaceuticals Frankfurt Exchange
132.39 EUR
Close of Nov 12, 2026
57.32 103.30
Market cap
EUR 14.4B
P/E
22.0x
P/B
10.26x
ROE
38.0%
Dividend yield
1.60%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is OFK.F undervalued?

Graham number

The Graham number of Orion Oyj cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Orion Oyj fundamental analysis

No fundamental analysis for Orion Oyj yet.

Orion Oyj stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart fa…

Full company profile